NAS10028,457+0.98%S&P7,679+1.46%GOLD$4,060+3.05%BTC$80,548+4.14%VIX17.57−15.65%latest tape · as of 16:09 UTC
The Screen · Energy · Oil & Gas Refining & Marketing
CVR Energy, Inc.
CVI · the NYSE · USD · Market cap $6.1B · 1,532 employees
CVR Energy, Inc., together with its subsidiaries, engages in renewable fuels and petroleum refining and marketing, and nitrogen fertilizer manufacturing activities in the United States.
FAIL · Does not pass the screen
48.60 USD
Price as of 3 Nov 2026Daily close, not a live quote
Screened 2026-11-03 · the tape above runs as of 16:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price48.60 USD at the 3 Nov 2026 close
Our value readOvervalued vs our fair value, as of 3 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.09, read 2026-11-02
Ethical does not pass the values gate
Price48.60 USD
Fair value41.30
Ethical score70.0/100
Value readOvervaluedas of 3 Nov 2026
Our investment reviews on this name
2026-10-30Read Markup56.82-14.5% to today Accumulation gives way to Markup after a 7% rise in 4 weeks
2026-10-02Read Accumulation53.15-8.6% to today Markup gives way to Accumulation after a 71% rise in 5 weeks
2026-08-26Read Markup31.15+56.0% to today ✓Distribution gives way to Markup
2026-07-02Read Distribution30.67+58.5% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CVR Energy, Inc. holds its Markup at $48.60. Consolidating, no directional conviction, held for 451 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 451 days
Price at the screen
$48.60
Valuation
90.64 trailing · 15.74 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.90
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
48.06%
Below 33%
Interest-bearing debt is 48.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
20.13%
Below 49%
Money owed to the company is 20.1% of assets, under the 49% limit.
Pass
Revenue purity
0.43%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CVR Energy,'s business is in a permissible area, but its interest-bearing debt is about 48% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CVI's ethical verdict changes
Today CVI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 3 Nov 2026: it trades above our $41.30 fair value estimate, 55.50% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. The price runs 17.7% above the base estimate.
Where our models see it going: fair-value estimate $41.30, with a range of $34.20 to $47.49, dated to the 2026-11-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 15.7x forward earnings, the price already runs ahead of the business. It trades 35% above our $41.30 fair value, so you would be buying at a premium, not a discount.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CVI trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markup$58.37+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$58.37+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$58.37+2.7%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$56.82+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup · changed$56.82-2.3%Entry 12
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$58.16-4.2%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$60.73+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$60.73-1.5%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32. Since the last review it entered the Titan Ethical 500; its composite score rose; dropped out of the Titan Ethical 500. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Accumulation$61.68+6.3%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32.
2026-10-14Accumulation$58.02+9.2%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 29%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (6 analysts) rates it underperform, with a mean price target of $32.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
